1-(1-benzyl-3,5-dimethyl-1H-pyrazol-4-yl)ethan-1-one | 40570-80-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(1-benzyl-3,5-dimethyl-1H-pyrazol-4-yl)ethan-1-one
• 英文别名: 3,5-Dimethyl-4-acetyl-1-benzyl-pyrazol；1-(1-benzyl-3,5-dimethyl-1H-pyrazol-4-yl)-ethanone；1-(1-Benzyl-3,5-dimethyl-1H-pyrazol-4-yl)ethanone；1-(1-benzyl-3,5-dimethylpyrazol-4-yl)ethanone
• CAS: 40570-80-7
• 化学式: C₁₄H₁₆N₂O
• 分子量: 228.294
• InChiKey: JPCBXDCAJZFPMF-UHFFFAOYSA-N

物化性质

• 沸点：
  377.1±30.0 °C(Predicted)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF<br/>[FR] COMPOSÉS À BASE DE PYRIDINONE ET DE PYRIDAZINONE ET UTILISATIONS MÉDICALES ASSOCIÉES
  申请人：HLA TIMOTHY

  公开号：WO2019173790A1

  公开（公告）日：2019-09-12

  The various examples presented herein are directed to compounds of the formula A-L1-Het1-L2-Cy1 or a pharmaceutical acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein: A is cycloalkyl, aryl, arylalkyl or heterocyclyl; Het1 is heterocyclyl containing at least two heteroatoms; Cy1 is a heterocyclyl; L1 is a bond, alkyl, alkenyl or alkynyl linker; L2 is an acyl or alkyl linker; and A and Cy1 are different. The compounds are useful in the treatment of fibrotic diseases, abnormal vascular leak and pathological angiogenesis.

  本文提供的各种示例涉及到以下公式的化合物A-L1-Het1-L2-Cy1或其药用可接受的盐、多型体、前药、溶剂合物或包合物，其中：A为环烷基、芳基、芳基烷基或杂环烷基；Het1为含有至少两个杂原子的杂环烷基；Cy1为杂环烷基；L1为键、烷基、烯基或炔基连接物；L2为酰基或烷基连接物；A和Cy1不同。这些化合物在治疗纤维化疾病、异常血管渗漏和病理性血管生成方面具有用途。
• PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF
  申请人：Cook, Timothy, H.

  公开号：EP3762377A1

  公开（公告）日：2021-01-13
• PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF
  申请人：Hla Timothy

  公开号：US20200407339A1

  公开（公告）日：2020-12-31

  The various examples presented herein are directed to compounds of the formula A-L 1 -Het 1 -L 2 -Cy 1 or a pharmaceutical acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein: A is cycloalkyl, aryl, arylalkyl or heterocyclyl; Het 1 is heterocyclyl containing at least two heteroatoms; Cy 1 is a heterocyclyl; L 1 is a bond, alkyl, alkenyl or alkynyl linker; L 2 is an acyl or alkyl linker; and A and Cy 1 are different. The compounds are useful in the treatment of fibrotic diseases, abnormal vascular leak and pathological angiogenesis.